SPINK1 and prostate carcinoma: Tomlins et al. [21] first showed that high levels of serine peptidase inhibitor Kazal type 1 (SPINK1), which occurs in about 10% of patients with prostate cancer, were correlated with higher rate of cancer recurrence.